Health8 hours ago
Novartis Advances Talks to Acquire Avidity Biosciences for Over $70
Novartis, the Swiss pharmaceutical giant, is reportedly in advanced negotiations to acquire Avidity Biosciences, a U.S.-based biotechnology company, for more than $70 per share. This information...